Medical Weight Loss · Eligibility Check
Am I a candidate for GLP-1 weight-loss medication?
A few quick questions to see whether you might meet the medical criteria for semaglutide (Wegovy) or tirzepatide (Zepbound), and what to confirm with a provider.
Educational only — not medical advice, a diagnosis, or a prescription. These are prescription medications; only a licensed medical provider can confirm eligibility, screen for contraindications, and prescribe. For adults; anyone under 18 must be assessed by a provider.
What this quiz checks
The questions follow the same screen a provider runs before booking. Each one maps to a factor that either supports the treatment, argues for a different one, or is a health flag that has to be cleared first.
- Weight-related conditions such as high blood pressure, type 2 diabetes, high cholesterol or sleep apnea, which factor into the FDA-approved eligibility criteria for semaglutide (Wegovy) and tirzepatide (Zepbound).
- Personal or family history of medullary thyroid cancer, or MEN 2, which is the boxed-warning contraindication for this class of medication.
- Pregnancy, breastfeeding, or plans to become pregnant in the next few months.
- Any serious allergic reaction to semaglutide, tirzepatide or another GLP-1 medication, plus other health flags a prescriber must screen for.
What your result means
A green result means you may meet the medical criteria and nothing you answered is a hard stop; a provider still confirms eligibility, screens you and decides whether to prescribe. A caution result means something needs a closer look before a prescription is considered. A stop result means a contraindication applies and this medication class is not appropriate without specialist review.
Whatever the result says, it is a starting point for the conversation with your provider, not a substitute for it. Bring your answers to the consultation so the time goes to planning rather than screening.
How this assessment works & sources
This self-check reflects FDA-approved eligibility and the boxed-warning contraindications for GLP-1 weight-loss medications (semaglutide / Wegovy and tirzepatide / Zepbound). It never diagnoses or prescribes — only a licensed medical provider can.
- Eligibility (BMI ≥30, or ≥27 with a weight-related condition), boxed warning & contraindications — FDA label: Wegovy · FDA label: Zepbound
- Average trial weight loss (semaglutide ~15%, tirzepatide ~20%) — NEJM STEP-1 · SURMOUNT-1
- Prescription-only, medical supervision — Mayo Clinic